natgillin/translations-raw huggingface dataset:
a compound wherein R1 is a hydrogen atom, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group or hexyl group, 
Medicinska oftalmološka otopina za uporabu prema Zahtjevu 1, gdje R' predstavlja atom vodika, metil skupinu, etil skupinu, propil skupinu, izopropil skupinu, butil skupinu, izobutil skupinu, sec-butil skupinu, tert-butil skupinu, pentil skupinu ili heksil skupinu,
3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dibromomethylidene-benzonorbornene-5-yl)amide (compound A-1.3). The designation of substituent X as chloro, fluoro or bromo means that both substituents X have the same meanings. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
In one embodiment of the present invention, the acid which forms part of the liquid salt of rasagiline has the general formula R—COOH, wherein R is a saturated or unsaturated, branched or unbranched C2-C23 alkyl. 
Sol rasagilina s kiselinom, naznačena time, da je sol pri 23"C tekuća, gdje kiselina ima opću formulu R-COOH, a R je zasićeni ili nezasićeni, razgranani ili nerazgranani C2-C23 alkil.
ii) determining the respective quantities of HC and of B2-microglobulin contained in said MHC-I complexes; 
ii) određivanje odgovarajućih količina HC i B2-mikroglobulina sadržanih u navedenim MHC-I kompleksima;
The plant cultivation system according to any one of claims 1 to 9, which further comprises an irrigation means for supplying the water or the nutrient fluid to a portion of said system which is positioned between said water impermeable material and said nonporous hydrophilic film, wherein said water or the nutrient fluid is fed in an amount which is the minimum required amount determined in respect of the growth stage of the plant being cultivated. 
Sustav za uzgoj biljaka prema bilo kojem od zahtjeva 1 do 5, gdje se voda ili nutritivna tekućina doprema kroz cijevi s kapaljkom u količini koja je minimalno potrebna, a što se određuje s obzirom na stadij rasta biljke koja se uzgaja.
heating the cooled suspension of (a) from a temperature in said second temperature range to a temperature in said first temperature range; 
(b) zagrijavanje ohlađene suspenzije iz (a) od temperature u navedenom drugom temperaturnom rasponu do temperature u navedenom prvom temperaturnom rasponu;
4 or a homologue thereof having an amino acid identity of at least 95%, preferably of at least 98%. 
4 ili njezin homolog koji ima identičnost amino kiseline od barem 95%, poželjno od barem 98%.
The rim block cage according to one of the preceding claims, characterized in that the flushing water distribution element (8) is jointly provided for all containers (3a, 3b, 3c, 3d). 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da je element za distribuciju vode za ispiranje (8) zajednički za sve spremnike (3a, 3b, 3c, 3d).
Examples of autoimmune diseases include, but are not limited to: MS, Crohn's disease, rheumatoid arthritis, type 1 diabetes mellitus, psoriasis, lupus, ulcerous colitis, vitiligo, coeliac disease, vasculitis, dermatomyositis, polymyositis, thyroiditis (Hashimoto, Graves), myasthenia gravis, Guillain-Barre syndrome, uveitis, flat lichen, temporal arteritis, sarcoidosis, dry syndrome (Sjöegren), bronchial asthma, pemphigus, ankylosing spondilitis, sclerodermia, fibromyalgia, rheumatic fever, etc. 
Uporaba prema zahtjevu 1, gdje je navedena autoimuna bolest multipla skleroza (MS), Chronova bolest, reumatoidni artritis, dijabetes melitus tipa 1, psorijaza, lupus, ulcerozni kolitis, vitiligo, celijakija, vaskulitis, dermatomiozitis, polimiozitis, tirozitis (Hashimoto, Graves), mijastenija gravis, Guillain-Barrov sindrom, uveitis, lihen planus, temporalni artritis, sarkoidoza, suhi sindrom (Sjčegren), bronhijalna astma, plikovnjača, ankilozantni spondilitis, sklerodermija, fibromialgija ili reumatska groznica.
amino acid residues at framework positions 1, 67 and 87 of the variable light chain according to the Kabat numbering scheme are substituted with non-human residues, wherein the non-human residue at framework position 1 is serine (S), the non-human residue at framework position 67 is tyrosine (Y) and the non-human residue at framework position 87 is phenylalanine (F); and 
(i) aminokiselinski ostatci na okvirnim pozicijama 1, 67 i 87 od varijabilnog slabog lanca prema shemi numeriranja Kabat, supstituirani s ne-humanim ostatcima, dok ne-humani ostatak na okvirnoj poziciji 1 je serin (S), ne-humani ostatak na okvirnoj poziciji 67 je tirozin (Y) i ne-humani ostatak na okvirnoj poziciji 87 je fenilalanin (F); i
Panel according to Claim 4, characterized in that the first detent means of the upper detent engagement point (20) has a detent projection (21), and in that the second detent means of the upper detent engagement point (20) has a detent depression (21a) adapted to said detent projection. 
Panel u skladu s patentnim zahtjevom 4, naznačen time što prvi zaponski element na gornjem mjestu međudjelovanja zapona (20) ima zaponsko izbočenje (21), te što drugi zaponski element na gornjem mjestu međudjelovanja zapona (20) ima zaponsko udubljenje (21a), prilagođeno za navedeno zaponsko izbočenje.
The rodent of claim 10, wherein the rodent expresses a population of antigen-specific antibodies in response to an antigen of interest wherein all antibodies from the population comprise: immunoglobulin light chain variable domains derived from the same single rearranged human light chain variable region gene sequence which comprises a substitution of at least one non-histidine codon with a histidine codon, and 
Glodavac prema zahtjevu 10, naznačen time, što glodavac izražava populaciju antitijela specifičnih za antigen kao odgovor na interesni antigen, pri čemu sva antitijela iz populacije sadrže: varijabilne domene imunoglobulinskog lakog lanca dobivene iz jedne iste preuređene genske sekvence varijabilne regije humanog lakog lanca koja sadrži supstituciju najmanje jednog nehistidinskog kodona histidinskim kodonom, i
• X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; 
• X predstavlja karboksilnu kiselinu ili karboksamid odabran iz skupine koju čine N-metil karboksamid, N,N-dimetil karboksamid, N-etil karboksamid i N,N-dietil karboksamid;
The binding polypeptide of any one of the preceding claims, wherein the side chain of the asparagine residue is linked to a glycan though a B-glycosylamide linkage. The binding polypeptide of claim 4, wherein the glycan is a biantennary glycan. 
bočni lanac asparaginskog ostatka na položaju aminokiseline 298, u skladu s EU označavanjem, vezan je na glikan preko B-glikozilamidne veze, i: glikan je biantenarni glikan;
A pharmaceutical composition comprising the human engineered antibody of claim 2, and a pharmaceutically acceptable carrier, diluent, or excipient. A method of treating a condition selected from the group consisting of clinical or pre-clinical Alzheimer's disease, prodromal Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy (CAA), comprising administering to a human in need thereof the human engineered antibody of claim 1 . 
Ljudsko modificirano protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačeno time što je namijenjeno upotrebi u liječenju stanja koje se bira iz skupine koju čine klinička ili pretklinička Alzheimerova bolest, prodromalna Alzheimerova bolest, Down sindrom, te klinička ili pretklinička cerebralna amiloidna angiopatija (CAA), koja se sastoji u primjeni na čovjeku kojem je to potrebno ljudskog modificiranog protutijela u skladu s patentnim zahtjevom 1.
In a further subgroup of compounds according to the invention, E represents aryl, such as phenyl, substituted by a fused substituted or unsubstituted heterocyclic ring, such as a nitrogen-containing heterocyclic ring. 
U daljnjoj podskupini spojeva prema ovom izumu E predstavlja aril, poput fenila, supstituiranog s kondenziranim supstituiranim ili nesupstituirani heterocikličkim prstenom, poput heterocikličkog prstena koji sadrži dušik.
A deuterated benzopyran compound of Formula (I) or a pharmaceutically acceptable salt thereof: wherein X is O 
Deuterirani benzopiranski spoj Formule (I) ili njegova farmaceutski prihvatljiva sol:
The recombinant adenovirus of claim 3, wherein said transgene is tumor necrosis factor, kras, or a functional portion thereof. 
Rekombinantni adenovirus u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni transgen faktor nekroze tumora, kras ili njegov funkcionalni dio.
—N3, or —C(—N═N—)(CF3), and wherein the benzyl group is optionally substituted with 1, 2 or 3 RA or R1 substituents. 
-C(-N=N-)(CF3), i gdje benzil grupa je po izboru supstituirana sa 1, 2 ili 3 RA ili R1 supstituenta, pod uvjetom da Spoj formule IIA, formule IIB ili formule IIC je različit od
In particular, the invention relates to a compound of formula IIBb 
Farmaceutska formulacija koja sadrži spoj formule IIB: O
A compound which is or a pharmaceutically acceptable salt, solvate and/or ester thereof. 
N ili njegovih farmaceutski prihvatljivih soli, solvata, estera, i/ili stereoizomera.
For parenteral routes such as intravenous, intrathecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administration. 
Kod parenteralnih načina davanja lijeka kao što je to intravenozno, ratekalno, intramuskularno i slični načini davanja, tipične doze su u količini koja odgovara polovini doze kakva se daje u oralnoj primjeni.
A process according to claim 8, wherein step a) is performed by evaporation under reduced pressure and/or heating and/or sparging the reaction mixture with an inert gas. 
9. Postupak prema zahtjevu 8, gdje se korak a) provodi isparavanjem pod sniženim tlakom i/ili zagrijavanjem i/ili 5
represents a C1-6 alkyl group; and each of R4, R5, and R6, which may be identical to or different from one another, represents a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylamino group, an optionally substituted aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R5 and R6 may form a ring together with the phenyl ring to which they are attached) or a salt thereof. 
predstavlja C1-6 alkil skupinu; predstavlja atom halogena, a i R6 koji mogu biti identični ili različiti jedan od drugog, predstavljaju atom vodika, atom halogena, C1-6 alkil skupinu, koja može imati atom halogena kao supstituent, ili C1-3 alkil skupinu ili njihovu sol.
A combination according to claim 1 or 2, wherein the long-acting B2 agonist is selected from the group comprising formoterol, salmeterol, GSK-597901, GSK-159797, KUL-1248, TA-2005 and QAB-149, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija sukladno patentnom zahtjevu 1 ili 2, naznačena time, da je kortikosteroid odabran iz skupine koja sadrži deksametazon, budesonid, beklometazon, triamcinolon, mometazon, ciklesonid, flutikazon, flunisolid, deksametazon natrij fosfat i njihove estere te (S)-fluorometil ester 6a,9a-difluoro-17a-[(2-furanilkarbonil)oksi - 118-hidroksM6a-metil-3-oksoandrosta-1,4-dien-17B-karbotionske kiseline.
a 5' sequence necessary for replication of the alphavirus, 
’ sekvencu neophodnu za replikaciju alfavirusa,
The use according to any one of claims 18 to 26, wherein the pharmaceutical composition further comprises an anticoagulant agent, preferably heparin, dicoumarol, acenocoumarol, enoxaparine or pentosan polysulfate. 
Upotreba prema bilo kojem zahtjevu 18 do 26, naznačena time, da farmaceutski sastav nadalje sadrži antikoagulantno sredstvo, ponajprije heparin, dikumarol, acenokumarol, enoksaparin ili pentosan polisulfat.
An isolated IL-23p19 antibody, wherein said antibody binds to human IL-23p19 or a fragment thereof at an epitope comprising portions of SEQ ID NO: 1 comprising amino acid residues 93-102, 93-110, and 127-137 of SEQ ID NO: 1. 
Izolirano IL-23p19 protutijelo, naznačeno time što se navedeno protutijelo veže za IL-23p19 ili za njegov ulomak na epitopu koji sadrži ostatke aminokiselina 93-102 SEQ ID NO: 1.
15 b and 16 b respectively show the status when the water pressure acts on the sealing material 8 . 
Slike 15b odnosno 16b prikazuju položaj kada tlak vode djeluje na materijal za brtvljenje 8.
Preparation of Tablets by Wet Granulation Method (Drug being Adsorbed onto the Excipients). 
Priprema tableta postupkom vlažne granulacije (lijek biva adsorbiran na ekscipijente).
The fuel gas supply line L1 upstream of the heat exchanger 3 has a first pump 2 for compressing the LNG to meet the pressure requirements for the high-pressure gas injection engine and supplying the LNG toward the high-pressure gas injection engine. 
Sustav dobave pogonskog plina za plovilo prema zahtjevu 1 naznačen time da druga crpka komprimira LNG na približno 100 do 300 bar manometarskog tlaka 1 zatim dovodi komprimirani LNG u visokotlačni plinski injekcijski motor.
The mixture was allowed to proceed for 15 minutes at room temperature and was terminated by the addition of 0.1 N HCl. 
Smjesa je procesirana kroz 15 minuta na sobnoj temperaturi i zaustavljena je dodatkom 0.1 N HC1.
for each of the plurality of calibration samples: 
Datum objave europske prijave patenta:
The pharmacokinetic and pharmacodynamic properties of non-aggregated (free monomeric) IL-2 are very different from those of microaggregated IL-2, and the two forms have different therapeutic indexes: aggregates that are too small are cleared by the body too quickly; aggregates that are too large can be insoluble and less active. 
Farmakokinetička i farmakodinamička svojstva neagregatnog (bezmonomernog) IL-2 su vrlo različita od onih od mikroagregatnog IL-2, a dva oblika imaju različite terapeutske indekse: agregati su premali i prebrzo se izlučuju iz organizma; agregati koji su preveliki mogu biti netopivi i manje aktivni.
Use of functionalized natural or synthetic calcium carbonate in a fast disintegrating dosage form, wherein said fast disintegrating dosage form comprises tablet, mini-tablets, granules or pellets, wherein said functionalized natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source, and wherein the functionalized natural or synthetic calcium carbonate has a BET specific surface area of from 15 m2/g to 200 m2/g, measured using nitrogen and the BET method according to ISO 9277:2010. 
Uporaba funkcionaliziranog prirodnog ili sintetskog kalcijevog karbonata u brzom obliku za razgradnju, naznačena time, da navedeni brzo dezintegrirajući oblik doziranja obuhvaća tablete, mini-tablete, granule ili pelete, pri čemu je navedemi funkcionalni prirodni ili sintetički kalcijev karbonat produkt reakcije prirodnog ili sintetskog kalcijevog karbonata s ugljičnim dioksidom i jedna ili više kiselina, pri čemu se ugljični dioksid formira in situ tretiranjem kiselinom i/ili iz kojeg se dobiva vanjski izvor, i pri čemu funkcionalizirani prirodni ili sintetski kalcijev karbonat ima BET specifičnu površinu površina od 15 m"g do 200 m'/g, mjerena korištenjem dušika i BET metoda prema ISO 9277: 2010.
Run Data: Column bed volume: 5 ml. 
Podaci o tijeku eksperimenta: Volumen korita kolone: 5 ml.
Furthermore the presence of cover increases the size of the faceplate portion protruding from the mounting surface of box. BRIEF SUMMARY OF THE INVENTION 
Nadalje, prisutnost poklopca povećava veličinu dijela čeone ploče koji dio je izbočen iz površine kutije u koju se montiraju komponente.
The composition of claim 6, wherein the bispecific ligand comprises a first arm that carries specificity for a minicell surface structure and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor. 
Sastav zahtjeva 6, naznačeno time da bispecifični ligand se sastoji od prvog kraka koji je nositelj posebnosti za strukturu površine ministanica, te drugi krak koji je nositelj posebnosti za receptore površine nefagocitnih stanica sisavaca.
The antibody for use according to any one of claims 1 to 5, wherein there is a post-administration reduction in absolute eosinophil count of at least about 25, at least about 50, at least about 75, at least about 100, at least about 125, at least about 150, at least about 175, at least about 200, at least about 225, at least about 250, at least about 275, at least about 300, at least about 325, at least about 350, at least about 375, at least about 400, at least about 425, at least about 450, at least about 475, or at least about 500 eosinophils / mm3. 
Protutijelo za uporabu prema bilo kojem od zahtjeva 1-4, naznačeno time da postoji smanjenje apsolutnog broja bazofila nakon davanja od barem 5, barem 10, barem 15, barem 20, barem 25, pri barem 30, barem 35, barem 40, najmanje 45, barem 50, barem 55, barem 60, barem 65 ili barem 70 bazofila/mm".
A formulation according to any one of the preceding claims for use in a method of treating a disease or disorder in a subject, the method comprising administering the formulation to a subject in an amount effective to treat the disease or disorder. 
Farmaceutska formulacija prema zahtjevu 1, naznačena time, da je za uporabu u postupku liječenja bolesti ili poremećaja kod subjekta, pri čemu taj postupak obuhvaća davanje subjektu učinkovite količine formulacije u svrhu liječenja bolesti ili poremećaja.
The solar energy collector according to claim 1, wherein the working fluid is hydrogen. A solar energy collector comprising: a radiation receiver, 
Prijamnik (2) sunčevog zračenja (1) prema zahtjevu 1 naznačen time što je radna tekućina vodik.
The significant increase in viscosity, observed as soon as pH=6, in particular at pH=5.5, of the infant milk according to the invention will provide significant effectiveness against regurgitations and/or reflux of the infant or child. 
Pripravak u skladu s patentnim zahtjevom 1 ili 13, naznačen time što je namijenjen upotrebi u sprječavanju ili liječenju regurgitacija i/ili refluksa kod dojenčeta ili kod djeteta.
In a particularly preferred embodiment, the total number of carbon atoms present in the pyrazine derivatives is within the range of 5-12, more preferably within the range of 9-12. 
U naročito poželjnom ostvarenju, ukupan broj atoma ugljika prisutnih u derivatima pirazina je unutar opsega od 5-12, poželjnije unutar opsega od 9-12.
styrene-butadiene copolymer-based solutions in an organic solvent, aqueous, terpolymer (butyl acrylate/2-ethylhexyl acrylate/vinyl acetate)-based dispersions, aqueous dispersions of a crosslinked acrylic acid polymer with isocyanate at a rate of 2% by weight of the total weight of the wet adhesive composition. 
Cc) otopina na bazi stiren-butadien kopolimera u organskom otapalu, d) vodenih disperzija na bazi terpolimera (butil akrilata/2-etilheksil akrilata/vinil acetata), e) vodenih disperzija umreženog akrilnog kiselog polimera s izocijanatom u omjeru od 2% prema težini u ukupnoj težini mokrog adhezivnog sastava,
This application is a §371 National Filing of International Patent Application No. 
EP 10186024.5 Datum podnošenja europske prijave patenta:
adding an aqueous phase; wherein the aqueous phase consists essentially of glycerin and the pH is adjusted to about 6 to about 8.8; and 
Gdje vodena faza u osnovi sadrži glicerin a pH je podešen na od oko 6 do oko 8.8;1 gdje je količina proizvoda razgradnje sa sljedećom formulom:
In a further preferred embodiment of the polypeptide dimer of the present invention, one or more N-glycosylation sites are inserted between the soluble gp130 molecule or variant or fragment and the Fc domain. 
Polipeptidni dimer prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što je topljiva gp130 molekula ili njena varijanta direktno fuzionirana sa zglobnom regijom Fc domene IgG1 proteina ili preko fleksibilne polipeptidne poveznice.
Procedure according to any one of the previous claims wherein, following the step of at least partial removal of the culture from the reactor, separation of the solid fraction which contains biomass and the liquid fraction which contains carbonates and/or bicarbonates is carried out through at least one technique selected from the group consisting of filtration, centrifugation, flocculation, electrocoagulation, ultrasound, evaporation, decantation or any combination thereof. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva naznačen time što se, nakon koraka u najmanju ruku djelomičnog uklanjanja kulture iz reaktora, odvajanje čvrste frakcije, koja sadrži biomasu, od tekuće frakcije, koja sadrži karbonate i/ili bikarbonate, provodi najmanje jednom tehnikom, koju se bira iz skupine koju čine filtriranje, centrifugiranje, flokulacija, elektrokoagulacija, ultrazvuk, otparavanje, dekantacija ili bilo koja njihova kombinacija.
The method according to any one of the preceding claims, wherein the mutation is present in exon 9 of PIK3CA, and the mutant allele specific primer comprises or consists of the sequence 5'-TTTCTCCTG A T T -3' (SEQ ID NO: 3) or is 5'-ACTCCATAGAAAATCTTTCTCCTG A T T -3' (SEQ ID NO: 4), wherein T indicates a mutation site and A indicates an additional mismatch. 
Metoda u skladu s bilo kojim spomenutim prethodnim zahtjevima, u sklopu koje je mutacija prisutna u egzonu 9 od PIK3CA, a početnica specifična za mutirani alel sastoji se od sekvence 5’-TTTCTCCTGATT-3’ (ID BR. SEKV.: 3) ili je 5’- ACTCCATAGAAAATCTTTCTCCTGATT-3’ (ID BR. SEKV.: 4), u kojoj se T odnosi na stranu mutacije, a A na dodatnu nepodudarnost.
contacting the immobilized ADA with drug labeled with a detectable label; and determining the presence or absence of said detectable label, to thereby determine the presence or absence of ADA in the sample, 
Postupak prema zahtjevu 1, naznačen time što korak određivanja obuhvaća dovođenje u kontakt imobiliziranog ADA s lijekom obilježenim oznakom koja se može detektirati; i određivanje prisutnosti ili odsutnosti navedene oznake koja se može detektirati, da se tako odredi prisutnost ili odsutnost ADA u uzorku.
A dry powder inhaler device, containing a dry powder formulation according to claim 1 . 
Inhalator za suhi prašak, koji sadrži formulaciju suhog praška prema bilo kojem od patentnih zahtjeva 1 do 8.
The compound of claim 1 or 5 and/or a pharmaceutically acceptable salt thereof, wherein one of R3 and R4 is in which n is 1 and each of Ra, Rb, and Rc, independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. 
Spoj patentnog zahtjeva 1 ili 5 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je jedno od R3 i Ru gdje n je 1 i svaki od R", R", i R9, nezavisno, je H, alkil, alkenil, alkinil, cikloalkil, heterocikloalkil, aril, ili heteroaril.
More preferably, the 9- cis -retinyl ester is 9- cis -retinyl succinate. Also provided are pharmaceutical compositions comprising the synthetic retinal derivative and a pharmaceutically acceptable vehicle. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 4, naznačen time, da je 9-cis-retinil ester 9-cis-retinil acetat.
The process as claimed in claim 1, wherein the temperature used in Step (v) is 80 °C to 82 °C. 
Postupak sukladno patentnom zahtjevu 1, naznačeno time, da je temperatura korištena u Koraku (v) 80 "C do 82 "€.
Compounds of formula I were also active in vivo against the carcinoma W256 (TGI=28%), most likely due to the higher solubility and thus passive transport into the tumor compared with other anti-folate agents. 
Spojevi formule I također su aktivni in vivo protiv karcinoma W256 (TGI = 28 %), najvjerojatnije uslijed više topljivosti i posljedično pasivnog transporta u tumor u usporedbi s ostalim anti-folat tvarima.